Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 542 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 6 Gy Clear all

Conditions: Pancreatic Cancer
Interventions: MEDI4736, Tremelimumab, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • New York, New York • The Bronx, New York

Conditions: Glioblastoma Multiforme
Interventions: Lucanthone, Temozolomide (TMZ), Radiation, Placebo; Drug · Radiation
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: La Jolla, California • Orange, California • Amherst, New York + 2 more

Conditions: Non-small Cell Lung Cancer
Interventions: M7824, Placebo, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin, Intensity Modulated Radiation Therapy (IMRT); Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 21
States / cities: Orange, California • Santa Monica, California • Colorado Springs, Colorado + 17 more

Conditions: Acute Leukemia, MDS
Interventions: Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant; Radiation · Drug · Device + 1 more
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions: Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan, CliniMACS CD34 Reagent System, Tacrolimus, Cyclophosphamide, Plerixafor, Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent, Thiotepa, Mycophenolate Mofetil (MMF), Ruxolitinib, Sirolimus; Drug · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Locally Advanced Rectal Cancer
Interventions: Intensity-modulated radiation therapy, 5-fluorouracil, Leucovorin, Oxaliplatin, Capecitabine, Accelerated Radiation Therapy, Irinotecan; Radiation · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Esophageal, Toxicity
Interventions: Manganese Superoxide Dismutase Plasmid Liposome, carboplatin, paclitaxel, Radiation Therapy; Genetic · Drug · Radiation
Lead sponsor: Joel Greenberger; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: cisplatin, epirubicin hydrochloride, fluorouracil, oxaliplatin, adjuvant therapy, neoadjuvant therapy; Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anal Cancer
Interventions: Radiation (reduced elective nodal dose (30.6 Gy), Capecitabine, Mitomycin c; Radiation · Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Cincinnati, Ohio • Columbus, Ohio • Burlington, Vermont

Conditions: Adult Soft Tissue Sarcoma
Interventions: Preoperative intensity modulated radiation therapy, Postoperative intensity modulated radiation therapy; Radiation
Lead sponsor: Mount Sinai Hospital, Canada; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Cleveland, Ohio • Portland, Oregon

Conditions: Lung Cancer
Interventions: Osimertinib, Cisplatin or Carboplatin; Pemetrexed or Paclitaxel, Radiation; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: La Jolla, California • Palo Alto, California

Conditions: Brain Tumor
Interventions: PPX +TMZ+XRT; Drug
Lead sponsor: howard safran; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms
Interventions: Modified FOLFIRINOX, Stereotactic Body Radiotherapy (SBRT); Drug · Radiation
Lead sponsor: Emory University; Other
Eligibility: 21 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Head and Neck Cancer
Interventions: Xevinapant, IMRT, Placebo; Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 7 more

Conditions: Head and Neck Cancer
Interventions: Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT); Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 5
States / cities: Miami Beach, Florida • Detroit, Michigan • The Bronx, New York + 2 more

Conditions: Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: Durvalumab, Surgery, Radiotherapy; Drug · Procedure · Radiation
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 9
States / cities: Chicago, Illinois • Boston, Massachusetts • Lowell, Massachusetts + 4 more

Conditions: Glioblastoma
Interventions: Gross total resection and Gliadel(R) wafers implanted, GammaKnife(R) stereotactic Radiosurgery, Standard fractionated radiation therapy, Temozolomide; Procedure · Radiation · Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Pancreatic Cancer
Interventions: Gemcitabine, Radiation Therapy, Erlotinib, Surgery; Drug · Radiation · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Interventions: PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer; Procedure · Radiation · Other + 1 more
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 20
States / cities: Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Ipilimumab, Radiotherapy (IMRT or 3-D CRT); Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: New York, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT), cisplatin or carboplatin-based; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Bone Metastases
Interventions: Hypofractionated Radiation Treatment, One Radiation Treatment, Questionnaire; Radiation · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 3
States / cities: Gilbert, Arizona • Voorhees Township, New Jersey • Houston, Texas

Conditions: Prostate Cancer
Interventions: 16 French Foley Catheter; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
Interventions: Pembrolizumab (immunotherapy), Quad-shot palliative radiotherapy; Drug · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)

Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

Preoperative vs Postoperative IMRT for Extremity/Truncal STS

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors

Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM

Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer

A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms

RAD 1801: Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate Stereotactic Body Radiotherapy

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition